Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: an international cross-sectional investigation.

Date publication

juillet 2025

Journal

Neuro-oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NOEL Georges

Tous les auteurs :
Boele FW, Frances SM, Darlix A, Ducray F, Cartalat S, Guerdoux E, Tabouret E, Burger MC, Rydén I, Malmstrom A, Vauleon E, Kazda T, Renovanz M, Werner JM, Welsh L, Sanghera P, Dehais C, Desideri I, McBain C, Mehta S, Lord H, Jena R, Foweraker K, Ashkan K, Engelhardt J, Bourg V, Herrlinger U, McLean AL, Hertler C, Haldbo-Classen L, Dahlrot RH, Noel G, Durando X, Hrab I, Razis E, Weller M, Muhic A, Klein M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40692477

Résumé

Patients with oligodendroglioma have a relatively favourable prognosis. The long-term impacts of the tumour itself and its treatment on health-related quality of life (HRQOL) and cognition remain largely unclear. We investigated associations between treatment and functioning of survivors of oligodendroglioma.

Mots clés

cognition, health-related quality of life, low-grade glioma, oligodendroglioma, survivorship

Référence

Neuro Oncol. 2025 07 19;: